Overview

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Status:
Withdrawn
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
To assess the influence of different dose strengths of BI 1181181 on single dose kinetics of midazolam (CYP3A4 probe drug), warfarin (CYP2C9 probe drug), omeprazole (CYP2C19 probe drug) and digoxin (P-gp probe drug)
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Digoxin
Midazolam
Omeprazole
Warfarin